Lack of association of a functionally relevant single nucleotide polymorphism of matrix metalloproteinase-1 promoter with systemic sclerosis (scleroderma)

被引:8
作者
Johnson, RW
Reveille, JD
McNearney, T
Fischbach, M
Friedman, AW
Ahn, C
Arnett, FC
Tan, FK
机构
[1] Univ Texas, Sch Med, Div Rheumatol & Clin Immunogenet, Houston, TX 77030 USA
[2] Univ Texas, Sch Med, Dept Internal Med, Clin Epidemiol Sect, Houston, TX 77030 USA
[3] Univ Texas, Med Branch, Dept Internal Med, Div Rheumatol, Galveston, TX USA
[4] Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Rheumatol, San Antonio, TX USA
关键词
systemic sclerosis; scleroderma; fibrosis; matrix metalloproteinase-1; genetics;
D O I
10.1038/sj.gene.6363768
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Matrix metalloproteinase 1 (MMP-1) is necessary for degradation of interstitial collagen types I, II, and III, which are the major constituents of the extracellular matrix (ECM). Increased expression of MMP-1 has been correlated with invasiveness of certain malignancies and cartilage degradation in rheumatoid arthritis. Increased transcriptional activity of MMP-1 has been reported with a single nucleotide polymorphism (SNP) of the MMP-1 promoter. Systemic sclerosis (SSc) is characterized by increased accumulation and turnover of collagen and other components of ECM. Previous studies have reported increased expression of MMP-1 transcripts in SSc fibroblasts. Therefore, we sought to determine if SSc patients with early disease (less than or equal to5 years) from a multi-ethnic cohort were more or less likely than ethnically-matched normal controls to have an increased frequency of the high promoter activity MMP-1 genotype and whether MMP-1 promoter genotypes correlated with any of the major clinical manifestations of SSc. The results show that the frequency of the high activity promoter genotype in either the heterozygous or homozygous state did not differ significantly between SSc patients and ethnically-matched controls, or between SSc patients with either diffuse or limited scleroderma. Furthermore, MMP-1 promoter genotypes did not significantly correlate with any of the major clinical manifestations of SSc.
引用
收藏
页码:273 / 275
页数:3
相关论文
共 16 条
  • [1] PRELIMINARY CRITERIA FOR THE CLASSIFICATION OF SYSTEMIC-SCLEROSIS (SCLERODERMA)
    不详
    [J]. ARTHRITIS AND RHEUMATISM, 1980, 23 (05): : 581 - 590
  • [2] Autoantibodies to fibrillarin in systemic sclerosis (scleroderma) - An immunogenetic, serologic, and clinical analysis
    Arnett, FC
    Reveille, JD
    Goldstein, R
    Pollard, KM
    Leaird, K
    Smith, EA
    Leroy, EC
    Fritzler, MJ
    [J]. ARTHRITIS AND RHEUMATISM, 1996, 39 (07): : 1151 - 1160
  • [3] Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases
    Borden, P
    Heller, RA
    [J]. CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 1997, 7 (1-2): : 159 - 178
  • [4] CLEMENTS P, 1995, J RHEUMATOL, V22, P1281
  • [5] Pathogenesis of scleroderma - Collagen
    Jimenez, SA
    Hitraya, E
    Varga, J
    [J]. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 1996, 22 (04) : 647 - +
  • [6] Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis
    Kuroda, K
    Shinkai, H
    [J]. ARCHIVES OF DERMATOLOGICAL RESEARCH, 1997, 289 (10) : 567 - 572
  • [7] LEROY EC, 1988, J RHEUMATOL, V15, P202
  • [8] Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis
    MacDougall, JR
    Matrisian, LM
    [J]. CANCER AND METASTASIS REVIEWS, 1995, 14 (04) : 351 - 362
  • [9] Systemic sclerosis in 3 US ethnic groups: A comparison of clinical, sociodemographic, serologic, and immunogenetic determinants
    Reveille, JD
    Fischbach, M
    McNearney, T
    Friedman, AW
    Aguilar, MB
    Lisse, J
    Fritzler, MJ
    Ahn, C
    Arnett, FC
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2001, 30 (05) : 332 - 346
  • [10] Rutter JL, 1997, J CELL BIOCHEM, V66, P322, DOI 10.1002/(SICI)1097-4644(19970901)66:3<322::AID-JCB5>3.3.CO